Iovance Biotherapeutics, Inc.'s (NASDAQ:IOVA) 26% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio

Simply Wall St18:34

Barclays Maintains Iovance Biotherapeutics(IOVA.US) With Buy Rating, Maintains Target Price $22

Futu NewsJan 13 19:31 · Ratings

Analysts Offer Insights on Healthcare Companies: Iovance Biotherapeutics (IOVA) and Vir Biotechnology (VIR)

TipRanksJan 12 20:40 · Ratings

Iovance Biotherapeutics Shares Are Falling Today: What's Going On?

BenzingaJan 11 00:24

Iovance Biotherapeutics, Inc.'s (NASDAQ:IOVA) Profit Outlook

Simply Wall StJan 6 19:48

10 Health Care Stocks With Whale Alerts In Today's Session

BenzingaDec 27, 2024 01:35